undamentalytics Newsletter
Sign in

Ginkgo Bioworks Holdings, Inc. (DNA) stock

Add to watchlist

Add holding +

NYSE: DNA NYSE Biotechnology Next results ~November 5, 2026

Ginkgo Bioworks Holdings, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Ginkgo Bioworks Holdings, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 5 selling0 purchases and 24 sales by directors and officers, last 12 monthsInsider trades
  • Funds96 adding, 57 cuttingOf 30 active managers that changed their stake, 18 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Ginkgo Bioworks Holdings files

Where Ginkgo Bioworks stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $112m, down 46.8% on a year earlier, a steeper fall than the 42.4% decline a quarter earlier. Free-cash-flow margin fell to -156.3% from -130.4% a year earlier. Operating margin narrowed to -259.9% from -141.7%. The diluted share count is up 8.9% on a year earlier, which dilutes existing holders. It passes 1 of our 2 financial-health checks.

Our model value for Ginkgo Bioworks Holdings is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Ginkgo Bioworks Holdings, Inc.'s trailing-twelve-month revenue fell 46.8% year on year, with a free-cash-flow margin of -156.3%.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 36.2% while net income grew 7.7%: a 29pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 46.8% over the last 12 months.
  • Loss-making. Operating margin is -259.9%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 118.2 points on a year ago.
  • Burning cash. Free cash flow was -156.3% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 55.7% of revenue: a real cost that cash-flow figures leave out.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.73 against an average estimate of -$0.70: missed by 4.7%
Revenue
$20m, down 48.5% on a year earlier
Share reaction
-9.3% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
total cash burn $-150m to $-125m (2026)
Next report
November 5, 2026; average EPS estimate -$0.54

Ginkgo Bioworks Holdings' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-12.1%
  • 1 week-1.7%
  • 1 month-20.2%
  • This year+18.5%
  • 1 year-24.2%
  • 5 years-98.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$112M
Operating margin
-259.9%
Net margin
-260.0%
EPS (TTM, diluted)
$-4.96

Growth

Revenue growth
−46.8%
Change in growth rate
−4.4 pts
Share count change
+8.9%

Cash

Free cash flow (TTM)
-$175M
FCF margin
-156.3%
Stock pay % of revenue
55.7%

Earnings

Last results
August 5, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Guidance
  4. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Ginkgo Bioworks Holdings, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$332.40$67.60$67.60$9.82$8.31$9.85
Market value$11.3bn$2.8bn$3.3bn$510m$461m$577m
+ Net debt (− = net cash)−$1.6bn−$1.3bn−$944m−$562m−$167m−$85m
Enterprise value$9.8bn$1.5bn$2.3bn−$52m$294m$493m
Multiples
Price / sales 36.0x5.9x13.1x2.2x2.7x5.2x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

12 /100

Weak moat

How hard Ginkgo Bioworks Holdings's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -41.4% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -327.2%; its worst year was -562.9%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -130.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $22m and EPS of −$0.54 (range −$0.58 to −$0.50) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.93 +20% $85m −50%
Next −$2.90 +1% $96m +13%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −14.3% on 90 days ago. In the last 30 days, 1 analyst raised Ginkgo Bioworks Holdings, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Ginkgo Bioworks Holdings, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.42 Current fiscal year, 60 days ago: −$3.20 Current fiscal year, 30 days ago: −$3.20 Current fiscal year, 7 days ago: −$3.20 Current fiscal year, Now: −$2.93 −$2.93 Next fiscal year, 90 days ago: −$3.21 Next fiscal year, 60 days ago: −$3.21 Next fiscal year, 30 days ago: −$3.21 Next fiscal year, 7 days ago: −$3.21 Next fiscal year, Now: −$2.90 −$2.90

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$3.42−$3.21
60 days ago −$3.20−$3.21
30 days ago −$3.20−$3.21
7 days ago −$3.20−$3.21
Now −$2.93−$2.90

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.70 −$0.73 −4.7%
Mar 2026 −$1.34 −$1.39 −3.7%
Dec 2025 −$1.11 −$0.77 +30.5%
Sept 2025 −$1.24 −$1.45 −16.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • Total cash burn 2026 $-150m to $-125m Non-GAAP Maintained
    “Ginkgo reaffirms expected total cash burn of ($150)-($125) million in 2026.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

3 analysts, Oct 2026
Buy00%
Hold133%
Sell267%

Monthly trend

  1. Oct 20261113
  2. Sep 20261113
  3. Aug 20261113

Counts of recommendations published by analysts covering Ginkgo Bioworks Holdings, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
15.5%
of tradable shares
Days to cover
2.4
at average volume
Short interest, 1 month
+16%
to October 15, 2026
Held by institutions
74%
of shares
Held by insiders
4.6%
of shares
Employees
485
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −24.2%

$12.99 on October 31, 2025 to $9.85

ThenNowEffect
Revenue (last 12 months) $210m $112m −46.8%
P/S multiple 3.3x 5.2x +55.3%
Share count 54m 59m −8.2%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years −85.0%

$65.60 on November 3, 2023 to $9.85

ThenNowEffect
Revenue (last 12 months) $326m $112m −65.7%
P/S multiple 8.9x 5.2x −42.2%
Share count 44m 59m −24.3%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
DNA−80%0%−86%−15%+19%
Industry peers (median)−56%−18%−28%−5%−27%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
DNA25%42%42%42%46%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
DNA−81%−50%−92%−66%−49%
S&P 500−25%−10%−8%−19%−9%

Worst fall since April 19, 2021: 99% from November 8, 2021 to September 9, 2024. Getting back needed a 11034% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$5.48 – $14.98
From 52-week high
−34.2%
vs 50-day average
+2.7%
vs 200-day average
+14.7%
Volatility (1 year)
103%
Beta vs S&P 500
3.23

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 11 down
typical move ±13.7%
After a week
2 up, 10 down
typical move ±18.9%
After a month
2 up, 10 down
typical move ±22.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −9.3% −0.4% −23.1% −25.8%
May 7, 2026 −11.4% +0.5% −22.1% −19.7%
February 26, 2026 −28.0% −1.0% −27.1% −36.8%
November 6, 2025 −22.8% −1.0% −31.0% −18.9%
August 7, 2025 −12.0% +0.7% −7.6% −19.8%
May 6, 2025 +6.9% −0.4% +17.3% +4.5%
February 25, 2025 −12.9% −0.4% −22.4% −36.4%
November 12, 2024 −1.8% −0.3% −26.4% +17.9%
May 9, 2024 −14.8% +0.7% −6.0% −42.8%
February 29, 2024 −15.1% +1.3% −21.1% −26.3%
January 10, 2024 −11.3% +0.5% −21.9% −6.6%
November 8, 2023 −18.2% −0.7% +1.3% −11.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Ginkgo Bioworks Holdings, Inc.
$100M $200M $300M $400M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $315M Revenue (TTM), FY23 Q4: $251.5M Revenue (TTM), FY24 Q1: $208.7M Revenue (TTM), FY24 Q2: $184.3M Revenue (TTM), FY24 Q3: $218M Revenue (TTM), FY24 Q4: $227M Revenue (TTM), FY25 Q1: $227.3M Revenue (TTM), FY25 Q2: $210.3M Revenue (TTM), FY25 Q3: $160M Revenue (TTM), FY25 Q4: $149.6M Revenue (TTM), FY26 Q1: $130.8M Revenue (TTM), FY26 Q2: $111.9M $111.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $315M
FY23 Q4 $251.5M
FY24 Q1 $208.7M
FY24 Q2 $184.3M
FY24 Q3 $218M
FY24 Q4 $227M
FY25 Q1 $227.3M
FY25 Q2 $210.3M
FY25 Q3 $160M
FY25 Q4 $149.6M
FY26 Q1 $130.8M
FY26 Q2 $111.9M
Revenue growth, TTM YoY Ginkgo Bioworks Holdings, Inc.
-60% -40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -40.3% Revenue growth, TTM YoY, FY23 Q4: -47.4% Revenue growth, TTM YoY, FY24 Q1: -46.5% Revenue growth, TTM YoY, FY24 Q2: -43.4% Revenue growth, TTM YoY, FY24 Q3: -30.8% Revenue growth, TTM YoY, FY24 Q4: -9.7% Revenue growth, TTM YoY, FY25 Q1: 8.9% Revenue growth, TTM YoY, FY25 Q2: 14.1% Revenue growth, TTM YoY, FY25 Q3: -26.6% Revenue growth, TTM YoY, FY25 Q4: -34.1% Revenue growth, TTM YoY, FY26 Q1: -42.4% Revenue growth, TTM YoY, FY26 Q2: -46.8% -46.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -40.3%
FY23 Q4 -47.4%
FY24 Q1 -46.5%
FY24 Q2 -43.4%
FY24 Q3 -30.8%
FY24 Q4 -9.7%
FY25 Q1 8.9%
FY25 Q2 14.1%
FY25 Q3 -26.6%
FY25 Q4 -34.1%
FY26 Q1 -42.4%
FY26 Q2 -46.8%
Operating margin (TTM) Ginkgo Bioworks Holdings, Inc.
-600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -291.2% Operating margin (TTM), FY23 Q4: -343.8% Operating margin (TTM), FY24 Q1: -396.1% Operating margin (TTM), FY24 Q2: -469.5% Operating margin (TTM), FY24 Q3: -291.0% Operating margin (TTM), FY24 Q4: -246.5% Operating margin (TTM), FY25 Q1: -203.5% Operating margin (TTM), FY25 Q2: -141.7% Operating margin (TTM), FY25 Q3: -207.9% Operating margin (TTM), FY25 Q4: -200.5% Operating margin (TTM), FY26 Q1: -221.9% Operating margin (TTM), FY26 Q2: -259.9% -259.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -291.2%
FY23 Q4 -343.8%
FY24 Q1 -396.1%
FY24 Q2 -469.5%
FY24 Q3 -291.0%
FY24 Q4 -246.5%
FY25 Q1 -203.5%
FY25 Q2 -141.7%
FY25 Q3 -207.9%
FY25 Q4 -200.5%
FY26 Q1 -221.9%
FY26 Q2 -259.9%
FCF margin (TTM) Ginkgo Bioworks Holdings, Inc.
-200% -150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -128.6% FCF margin (TTM), FY23 Q4: -133.7% FCF margin (TTM), FY24 Q1: -154.4% FCF margin (TTM), FY24 Q2: -188.0% FCF margin (TTM), FY24 Q3: -177.7% FCF margin (TTM), FY24 Q4: -168.3% FCF margin (TTM), FY25 Q1: -151.9% FCF margin (TTM), FY25 Q2: -130.4% FCF margin (TTM), FY25 Q3: -117.0% FCF margin (TTM), FY25 Q4: -119.5% FCF margin (TTM), FY26 Q1: -128.6% FCF margin (TTM), FY26 Q2: -156.3% -156.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -128.6%
FY23 Q4 -133.7%
FY24 Q1 -154.4%
FY24 Q2 -188.0%
FY24 Q3 -177.7%
FY24 Q4 -168.3%
FY25 Q1 -151.9%
FY25 Q2 -130.4%
FY25 Q3 -117.0%
FY25 Q4 -119.5%
FY26 Q1 -128.6%
FY26 Q2 -156.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 54 77 314 478 251 227 170 112
EBITDA −61 −123 −1,799 −2,166 −794 −497 −256 −237
Operating income −72 −137 −1,828 −2,209 −864 −560 −315 −291
Net income −119 −127 −1,830 −2,105 −893 −547 −313 −291
Diluted EPS −$4.00 −$4.00 −$55.60 −$50.20 −$18.37 −$10.54 −$5.64 −$4.96
Growth (year on year)
Revenue — +41.5% +309.4% +52.2% −47.4% −9.7% −25.1% −46.8%
Margins
EBITDA margin −112.3% −160.7% −573.4% −453.5% −315.7% −218.8% −150.6% −211.6%
Operating margin −132.1% −178.8% −582.6% −462.4% −343.8% −246.5% −185.3% −259.9%
Net margin −220.2% −165.2% −583.1% −440.6% −355.1% −240.9% −183.8% −260.0%
Free-cash-flow margin −123.4% −252.6% −98.9% −63.7% −133.7% −168.3% −105.0% −156.3%
Cash flow
Cash from operations −45 −136 −254 −252 −296 −320 −171 −170
Capital spending 22 58 57 52 41 63 8 5
Free cash flow −67 −194 −310 −304 −336 −382 −179 −175
Stock-based pay 1 0 1,606 1,931 230 112 82 62
Free cash flow after stock pay −68 −194 −1,916 −2,235 −566 −494 −260 −237
Balance sheet
Cash 495 381 1,550 1,316 944 562 167 85
Total debt 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −495 −381 −1,550 −1,316 −944 −562 −167 −85
Diluted shares 29m 32m 34m 42m 49m 52m 55m 59m
Returned to shareholders
Buybacks 0 0 25 0 0 — — —
Total returned 0 0 25 0 0 — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 2 checks passed · June 30, 2026
What it owns · $990m
Short-term assets $333mLonger-term assets $658m
What it owes, and who funded it · $990m
Short-term liabilities $73mLonger-term liabilities $497mShareholders' equity $420m
  • Short-term assets cover short-term liabilities $333m of assets due within a year against $73m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $333m short-term assets against $497m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Ginkgo Bioworks Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+8.9%
year over year
R&D spending
192.7%
of revenue
Days sales outstanding
42 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated DNA SPRY RCUS XNCR MESO KYMR Median
Revenue, last 12 months $112m $117m $117m $105m $120m $102m $58m
Revenue growth, last 12 months −46.8% 4.1% −55.3% −28.6% 599.2% 133.8% 12.2%
Revenue growth, 3-year average −30.0% 711.3% −1.1% −2.5% — 29.7% 13.1%
Revenue growth, latest quarter −48.5% 114.2% −74.4% 17.5% — −100.0% 10.2%
Gross margin — — — — 86.1% 0.0% 82.9%
Operating margin −259.9% −185.0% −415.4% −205.8% — −396.0% −191.1%
Operating margin, 3-year average −290.4% <−999% −221.0% −136.0% — −461.5% −361.6%
Net margin −260.0% −184.2% −393.2% −155.6% −47.8% −341.8% −172.8%
Cash from operations / revenue −152.2% −168.0% −405.1% −196.1% −36.4% −281.3% −162.3%
Free-cash-flow margin −156.3% −168.1% −406.0% −198.4% −37.1% −282.6% −156.7%
Free-cash-flow margin, 3-year average −158.2% <−999% −214.9% −128.0% — −326.1% −306.5%
Stock pay / revenue 55.7% 26.7% 53.8% 37.2% 12.4% 66.7% 20.7%
Change in share count 8.9% −3.9% 22.7% 5.2% 7.2% 17.6% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Cell Engineering Revenue $133M 78.0% ▼ 23.7%
Services $37.4M 22.0% ▼ 29.5%
Products $0 0.0% —

From Ginkgo Bioworks Holdings, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$349M
Institutions reporting
181
Shares held vs prior quarter
▲ 12.4%
Positions opened / closed
29 / 19

Top buyers and sellers, Q2 2026: 96 institutions bought and 57 sold ; the biggest buyer was Blackrock, Inc (+641K shares) and the biggest seller Goldman Sachs Group Inc (−322K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $42.4M 4.3M 12.2% ▲ 17.6%
Viking Global Investors LP $35.4M 3.6M 10.1% 0.0%
Erste Asset Management Gmbh $25.9M 2.5M 7.4% ▲ 30.3%
Baillie Gifford & Co $23.7M 2.4M 6.8% 0.0%
Vanguard Capital Management LLC $20.7M 2.1M 5.9% ▲ 9.0%
Anchorage Capital Group, L.L.C. $17.3M 1.7M 5.0% 0.0%
Legal & General Group PLC $16.5M 1.7M 4.7% ▲ 0.5%
State Street Corp $14.6M 1.5M 4.2% ▲ 9.3%
Geode Capital Management, LLC $12.1M 1.2M 3.5% ▲ 21.1%
Vanguard Portfolio Management LLC $9.3M 938K 2.7% ▲ 65.8%
Allianz Asset Management Gmbh $7.8M 786K 2.2% ▲ 12.2%
UBS Group AG $6.9M 692K 2.0% ▲ 18.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Ginkgo Bioworks Holdings, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $5M 24 trades by 5 insiders · 1% under pre-set plans
Net ▼ $5M net selling
Insider Date Trade Shares Price Value
Kelly Jason R See remarks October 19, 2026 Sell 45,682 $10.14 $463,353
Shetty Reshma P. See remarks October 19, 2026 Sell 18,803 $10.14 $190,719
Shetty Reshma P. See remarks October 19, 2026 Sell 22,369 $10.14 $226,889
Canton Barry 10% owner October 19, 2026 Sell 22,369 $10.14 $226,889
Canton Barry 10% owner October 19, 2026 Sell 18,803 $10.14 $190,719
Coen Steven P. See remarks October 19, 2026 Sell 766 $10.14 $7,770
Coen Steven P. See remarks October 5, 2026 Sell pre-set plan 2,403 $15.00 $36,045
Henry Christian O Director September 15, 2026 Sell 5,000 $7.08 $35,400
Coen Steven P. See remarks August 24, 2026 Sell 330 $6.98 $2,303
Coen Steven P. See remarks July 17, 2026 Sell 752 $7.90 $5,941
Coen Steven P. See remarks May 22, 2026 Sell 307 $8.33 $2,557
Coen Steven P. See remarks April 17, 2026 Sell 324 $7.95 $2,576

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 7, 2026
  • February 26, 2026
  • November 6, 2025
  • August 7, 2025
  • May 6, 2025

Recent SEC filings

Data status

When each part of this page on Ginkgo Bioworks Holdings, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Ginkgo Bioworks Holdings, Inc. in brief

What does Ginkgo Bioworks Holdings, Inc. do?
Ginkgo Bioworks Holdings, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Ginkgo Bioworks Holdings, Inc.'s stock ticker?
Ginkgo Bioworks Holdings, Inc. trades under the ticker DNA on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Ginkgo Bioworks Holdings, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Ginkgo Bioworks Holdings, Inc. reported revenue of $112M, 46.8% lower than a year earlier, according to its SEC filings.
What is Ginkgo Bioworks Holdings, Inc.'s free cash flow?
Ginkgo Bioworks Holdings, Inc.'s free-cash-flow margin is -156.3% of revenue over the trailing twelve months.
Who are Ginkgo Bioworks Holdings, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Viking Global Investors LP and Erste Asset Management Gmbh. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Ginkgo Bioworks Holdings, Inc.'s market cap?
On November 2, 2026, Ginkgo Bioworks Holdings, Inc.'s market capitalisation was about $577M and net debt of -$84.5M. Market figures come from third-party market data and may be delayed.
Who are Ginkgo Bioworks Holdings, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Ginkgo Bioworks Holdings, Inc. are ARS Pharmaceuticals, Inc., Arcus Biosciences, Inc., Xencor Inc, Mesoblast LTD and Kymera Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Ginkgo Bioworks Holdings, Inc.'s.
Are insiders buying or selling Ginkgo Bioworks Holdings, Inc. stock?
Over the last 12 months, Ginkgo Bioworks Holdings, Inc.'s directors and officers reported 0 open-market purchases and 24 sales on Form 4. The insider trading page charts every trade.
When is Ginkgo Bioworks Holdings, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Ginkgo Bioworks Holdings, Inc. announces its own schedule.